ATE235513T1 - Opioid-konjugate mit endogenen trägerproteinen - Google Patents

Opioid-konjugate mit endogenen trägerproteinen

Info

Publication number
ATE235513T1
ATE235513T1 AT01121557T AT01121557T ATE235513T1 AT E235513 T1 ATE235513 T1 AT E235513T1 AT 01121557 T AT01121557 T AT 01121557T AT 01121557 T AT01121557 T AT 01121557T AT E235513 T1 ATE235513 T1 AT E235513T1
Authority
AT
Austria
Prior art keywords
patient
conjugates
antinociceptive
conjugate
vivo
Prior art date
Application number
AT01121557T
Other languages
English (en)
Inventor
Alan M Ezrin
Dominique P Bridon
Darren L Holmes
Peter Milner
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE235513T1 publication Critical patent/ATE235513T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT01121557T 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen ATE235513T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
ATE235513T1 true ATE235513T1 (de) 2003-04-15

Family

ID=22057753

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98956656T ATE216402T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen
AT01121557T ATE235513T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98956656T ATE216402T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Country Status (9)

Country Link
EP (2) EP1028971A2 (de)
JP (2) JP2001522817A (de)
AT (2) ATE216402T1 (de)
AU (3) AU1519799A (de)
CA (2) CA2309205A1 (de)
DE (2) DE69804974T2 (de)
ES (1) ES2173641T3 (de)
IL (1) IL135835A0 (de)
WO (3) WO1999024074A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP4209086B2 (ja) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
ES2257298T3 (es) * 1999-05-17 2006-08-01 Conjuchem, Inc. Proteccion de peptidos terapeuticos endogenos contra la actividad de la peptidasa a traves de la conjugacion con componentes sanguineos.
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
EP1264840B1 (de) 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
EA006484B1 (ru) 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2)
ES2277173T3 (es) 2001-05-31 2007-07-01 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones por vih.
ATE466953T1 (de) 2003-01-17 2010-05-15 Advanced Proteome Therapeutics Verfahren zur identifizierung aktivierter polymer-komplexe zur sekundären stellen-spezifischen modifikation von protein ziel-gruppen.
DE602005022239D1 (de) 2004-04-23 2010-08-19 Conjuchem Biotechnologies Inc Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2114437A2 (de) 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modifizierte peptide mit corticotropinfreisetzungsfaktor und verwendungen davon
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
EP3201166A4 (de) * 2014-07-18 2018-06-27 Biocogent, LLC Zusammensetzungen und verfahren mit salicylaten und polysalicylaten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59138958A (ja) * 1983-01-31 1984-08-09 Mitsubishi Chem Ind Ltd 抗血清
US4784955A (en) * 1984-09-21 1988-11-15 Miles Inc. Immunogen conjugates and the use thereof in a dihydropyridine assay
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
DE69804974D1 (de) 2002-05-23
JP2001522817A (ja) 2001-11-20
AU1312799A (en) 1999-05-31
EP1007561A2 (de) 2000-06-14
DE69804974T2 (de) 2002-11-07
CA2301799A1 (en) 1999-05-20
WO1999024462A2 (en) 1999-05-20
CA2301799C (en) 2007-08-07
ES2173641T3 (es) 2002-10-16
AU750387B2 (en) 2002-07-18
WO1999024076A2 (en) 1999-05-20
WO1999024074A2 (en) 1999-05-20
WO1999024076A9 (en) 2000-06-08
AU1385699A (en) 1999-05-31
WO1999024074A3 (en) 1999-08-19
CA2309205A1 (en) 1999-05-20
EP1007561B1 (de) 2002-04-17
AU1519799A (en) 1999-05-31
DE69812727D1 (de) 2003-04-30
EP1028971A2 (de) 2000-08-23
WO1999024462A3 (en) 1999-08-26
WO1999024076A3 (en) 1999-08-19
JP2001522863A (ja) 2001-11-20
ATE216402T1 (de) 2002-05-15
IL135835A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
ATE216402T1 (de) Opioid-konjugate mit endogenen trägerproteinen
Ringsdorf Structure and properties of pharmacologically active polymers
CA2064689A1 (en) Stabilized protein or peptide conjugates
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
AU2259392A (en) Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
CA2066228A1 (en) Tgf-beta protein compositions for inhibition of cell proliferation
BRPI0416028A (pt) composto, conjugados do composto e de anticorpo-medicamento, composições farmacêuticas, usos dos conjugados, métodos para tratamento de cáncer, de uma doença auto-imune, de uma doença infecciosa e de um paciente, método para inibir a proliferação ou matar as células de tumor ou células cancerìgenas, método de inibição do crescimento de células de tumor, análise para detectar células de cáncer e artigo de manufatura
WO1988000834A1 (en) Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
Poznansky et al. Insulin: carrier potential for enzyme and drug therapy
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
US5411943A (en) Hepatoma treatment with somatostatin analogs
Habberfield et al. Vitamin B12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo
AU2002238687B2 (en) Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
Wright et al. Local action of parathyroid hormone (1–34) and (1–84) at the parotid gland of sheep
MD1135F1 (en) Paradontium treatment method
CA2326720A1 (en) Hemoglobin-haptoglobin complexes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties